MARIA APARECIDA NAGAI
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Par-4 in apoptosis during human salivary gland development and tumorigenesis(2022) COUTINHO-CAMILLO, C. M.; GOMES, A. N. de Mello; PAULA, F. D.; NAGAI, M. A.; LOURENCO, S. V.Human salivary glands (SGs) are complex structures comprising a system of ducts and acini formed in gradual stages termed the prebud, initial bud, pseudoglandular, canalicular, and terminal bud. This process involves growth, proliferation, differentiation, migration, and cell death. Studies in human specimens and in vitro models have demonstrated that apoptosis seems to be important not only during the early developmental stages of the salivary glands, but also contributes to the tumorigenic process and impacts the patient's treatment. Therefore, the screening of proteins associated with apoptosis might contribute to the development of different strategies focusing on cancer diagnosis, prognosis, and target therapies. The prostate apoptosis response-4 (PAR-4) is a 38 kDa protein encoded by the PAWR gene (PKC apoptosis WT1 regulator) that is ubiquitously expressed in different tissues and plays a role in both the intrinsic and extrinsic apoptotic pathways. This chapter explores the current knowledge on the expression of Par-4 during human salivary gland development and in the most frequent salivary gland tumors (benign: pleomorphic adenoma and malignant: adenoid cystic carcinoma and mucoepidermoid carcinoma). In addition to the application of Par-4 as a tumor prognostic marker, the use of targeted therapies against Par-4 is increasingly considered as an important strategy for cancer treatment. © Springer Nature Switzerland AG 2021. All rights reserved.
bookPart Modulação da expressão gênica e epigenética(2022) SANTOS, Nathalia Leal; NAGAI, Maria Aparecida; FURUYA, Tatiane KatsuebookPart Alterações genéticas no câncer(2015) ENCINAS, Giselly; MAZZOTTI, Tatiane Katsue Furuya; NAGAI, Maria AparecidabookPart Oncogenes e genes supressores de tumor(2013) NAGAI, Maria Aparecida- Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes(2014) NAGAI, M. A.; BRENTANI, M. M.The estrogens play important role in the homeostatic maintenance of several target tissues including those in the mammary gland, uterus, bone, cardiovascular system, and brain. Most of estrogen's action is thought to be mediated through its nuclear estrogen receptors, ERα and ERβ, which are members of the nuclear receptor superfamily that act as ligand-induced transcription factors. Acting via its receptors, estrogen also plays an essential role in the development and progression of human breast cancer. The ER and progesterone receptor (PR), which is regulated by estrogen via ER, have been used as prognostic markers in the clinical management of breast cancer patients. However, the prognosis of a patient with ER+/PR+ breast cancer can be highly variable and a significant proportion of hormone receptor positive breast cancers do not respond to endocrine therapy. The identification of estrogen receptor target genes may improve our understanding of the role played by estrogens in breast cancer making it possible to better tailor hormone treatments and improve a patient's response to hormonal therapy. In this review, we explore the literature for data regarding the identification of estrogen receptor-regulated genes in breast cancer cell lines and breast tumor biopsies using high throughput technologies such as serial analysis of gene expression (SAGE) and cDNA microarrays. © 2014 Bentham Science Publishers Ltd. Published by Elsevier Inc. All rights reserved.